Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Actavis

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs.

Actavis

Deal Watch August 2016

Deal Watch August 2016 Apr 14 / Hostile. Valeant. Allergan. $54bn. Allergan sold to Actavis for $66bn. ... Allergan sells to Actavis not Valeant. As far as we know, Sanofi did not have any business relationships with Medivation unlike Pfizer who had a deal running from 2008 to

Teva acquires Allergan’s generics operations in $38.8bn deal

Teva acquires Allergan’s generics operations in $38.8bn deal Teva Pharmaceutical Industries, the global leader in generic drugs sales, has further bolstered its market dominance with the purchase of Allergan's generics business, Actavis Generics. ... Erez Vigodman, president and chief executive at Teva, said that

AZ gets EU green light for new antibiotic Zavicefta

AZ gets EU green light for new antibiotic Zavicefta AZ and Actavis are also testing avibactam in combination with other beta lactam antibiotics, with phase III trials ongoing looking at the drug alongside aztreonam and ceftaroline.

Merck starts pivotal trials of new antibiotic combination

Merck starts pivotal trials of new antibiotic combination The combination has also been approved in the US - where it is sold by Actavis - as Avycaz.

CHMP backs AZ's 'superbug' antibiotic product

CHMP backs AZ's 'superbug' antibiotic product In the US, Actavis (now operating as Allergan) has been granted FDA approval for another combination of ceftazidime and avibactam, which is sold as Avycaz. ... Actavis gained rights to the combination after buying Forest Labs, which originally developed

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics